This patient had a TPM3::NTRK1 fusion PTC and was treated with larotrectinib for 24 weeks prior to the initial administration of 131I. The baseline diagnostic 123I scan showed faint uptake in the pulmonary disease without significant uptake noted in the largest metastatic lesions. Here, TPM3 is linked to lung disorder.